Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
Authors:
Open Access
- 19 July 2022
- journal article
- editorial
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (7) , 100691
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Amgen
- GlaxoSmithKline
This publication has 8 references indexed in Scilit:
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerNew England Journal of Medicine, 2022
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2020
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.2018
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant dataThe Lancet, 2014
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointThe Lancet Oncology, 2014
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010